Empiric Antibiotic Selector | By Site, Severity & Allergy

Q: Is this tool a substitute for a local antibiogram or an ID consult?

No. It provides a reasonable empiric starting point based on current guidelines, but local resistance patterns vary widely. Always substitute your institution's antibiogram and protocols, and consult Infectious Diseases for resistant organisms (CRE, DTR-Pseudomonas), persistent S. aureus bacteremia or candidemia, and complex cases.

Q: My patient reports a penicillin allergy. Can I still use a cephalosporin or carbapenem?

In most cases, yes. True cross-reactivity is about 1-2 percent (not the historically quoted 10 percent), and is under 1 percent for cephalosporins with a different side chain. For non-severe or unconfirmed allergy, cephalosporins and carbapenems can be used as-is. Even after anaphylaxis to penicillin, a side-chain-different cephalosporin or a carbapenem is generally safe. Reserve aztreonam-based regimens for the rare patient who must avoid all beta-lactams.

1. Primary infection site

Choose the single most likely source. For multiple or unclear sources, use “Undifferentiated sepsis”.

2. Acquisition

3. Known colonization / prior resistant isolate (select all that apply)

4. Host & severity

Severity sets urgency (time-to-antibiotic), escalation thresholds, and IV-vs-oral; spectrum also depends on source and resistance risk — review the conditional prompts. “Stable” enables narrower, oral-switch-friendly therapy.

5. Penicillin / β-lactam allergy

Empiric Recommendation

Before you prescribe

⛔ Not for: meningitis / CNS infection · pediatrics / neonates · pregnancy · infective endocarditis. Adults, normal renal function only.

Draw blood cultures (≥ 2 sets) + site cultures before the first dose — but do not delay antibiotics beyond the time target if cultures cannot be obtained promptly (especially in shock).
Time-to-antibiotic: septic shock / probable sepsis ≤ 1 h; possible sepsis ≤ 3 h.
Source control (drainage / line removal / debridement) is as important as antibiotics.
Reassess at 48–72 h: de-escalate on culture & susceptibility; stop if infection excluded.
This is an empiric starting point — substitute your local antibiogram & institutional protocol; consult ID for CRE, DTR-Pseudomonas, persistent S. aureus bacteremia / candidemia, and complex cases.

⚠️ Scope

Adults with normal renal function. Not for meningitis / CNS infection, pediatrics / neonates, pregnancy, or infective endocarditis (use dedicated guidance for endocarditis). Single primary site (use “Undifferentiated sepsis” for multiple/unclear). Adjust every dose for renal function, weight, and therapeutic drug monitoring.

Recent Updates

Every regimen card now lists an evidence-based alternative agent for when the first choice can’t be used (intolerance, toxicity, or shortage) — e.g., cefotaxime or a respiratory fluoroquinolone for ceftriaxone, imipenem-cilastatin for meropenem, and linezolid or daptomycin (by site) for vancomycin. Deep-resistant niches show “no equivalent — ID consult”.
Empiric coverage follows a risk-stratified philosophy (Surviving Sepsis Campaign 2026): even in shock, MRSA, double Gram-negative, and antifungal coverage are not routine — add them only when risk factors are present.
The first-ever IDSA 2025 complicated-UTI guideline and the SIS 2024 intra-abdominal guideline now govern those sites; for invasive ESBL infection, avoid piperacillin-tazobactam (MERINO). For metallo-β-lactamase–producing CRE, fixed-dose aztreonam-avibactam is now FDA-approved (2025).
Penicillin allergy reframed: true cephalosporin cross-reactivity is ~1–2% (not 10%); side-chain–different cephalosporins and carbapenems are safe in most patients.

Source: Prescott HC, et al. Surviving Sepsis Campaign 2026; Trautner BW, et al. IDSA cUTI 2025; Carmeli Y, et al. REVISIT (aztreonam-avibactam) 2025; Khan DA, et al. Drug Allergy Practice Parameter 2022; Tamma PD, et al. IDSA AMR Gram-negative 2024; Liu C, et al. IDSA MRSA 2011; Stevens DL, et al. IDSA SSTI 2014. (See Sources.)

Key Knowledge Points

Correctly identifying the likely source is the single most important driver of empiric choice.
Cultures before antibiotics, then de-escalate at 48–72 h — empiric therapy is meant to be narrowed.
Resistance coverage should track risk factors and local prevalence, not reflex broad-spectrum use.
Doses shown are normal-renal-function adult starting doses — always adjust for the individual patient.

About This Tool

The Empiric Antibiotic Selector suggests a reasonable empiric regimen — the antibiotics to start before culture results return — based on the infection site, where it was acquired, known colonization, host factors, and β-lactam allergy. It distills current IDSA, ATS, SIS, and Surviving Sepsis Campaign guidance into a single workflow, emphasizing antibiotic stewardship: cover the likely pathogens, avoid unnecessary breadth, and narrow therapy as soon as data allow.

How to Use This Tool

Select the infection site — the primary driver of likely pathogens.
Set acquisition (community vs hospital/healthcare) — this distinguishes CAP from HAP/VAP and raises the resistance tier.
Flag known colonization or prior resistant isolates (select all that apply).
Mark host and severity (immunocompromised/neutropenic; septic shock) and any β-lactam allergy.
Review the regimen, the conditional add-on prompts, and the always-do steps.

Frequently Asked Questions (FAQ)

1. Is this tool a substitute for a local antibiogram or an ID consult?

No. It provides a reasonable empiric starting point, but local resistance patterns vary widely. Always substitute your institution’s antibiogram and protocols, and consult Infectious Diseases for resistant organisms (CRE, DTR-Pseudomonas), persistent S. aureus bacteremia or candidemia, and complex cases.

2. Why doesn’t septic shock automatically add MRSA, double Gram-negative, or antifungal coverage?

The 2026 Surviving Sepsis Campaign recommends risk stratification rather than reflexive broad coverage. Unnecessary anti-MRSA, dual Gram-negative, or antifungal therapy increases toxicity, C. difficile, resistance, and acute kidney injury without improving outcomes. Add each only when specific risk factors are present.

3. My patient reports a penicillin allergy. Can I still use a cephalosporin or carbapenem?

In most cases, yes. True cross-reactivity is about 1–2% (not the historically quoted 10%), and under 1% for cephalosporins with a different side chain. For non-severe or unconfirmed allergy, cephalosporins and carbapenems can be used as-is. Even after anaphylaxis to penicillin, a side-chain–different cephalosporin or a carbapenem is generally safe. Reserve aztreonam-based regimens for the rare patient who must avoid all β-lactams.

4. Should I treat ESBL infection with piperacillin-tazobactam?

Not for invasive infection. The MERINO trial showed higher mortality with piperacillin-tazobactam than meropenem for ESBL bloodstream infection. Use a carbapenem (ertapenem if stable; meropenem if severe, ICU, or low albumin). For ESBL complicated UTI, oral TMP-SMX or a fluoroquinolone is preferred if susceptible.

5. How long should empiric therapy continue?

Empiric therapy is meant to be temporary. Obtain cultures before the first dose, reassess at 48–72 hours, and de-escalate to the narrowest effective agent once susceptibility data return. Many infections now have evidence-based short courses, and IV-to-oral switch is appropriate once the patient is stable.

Related Tools

📖 Sources:

⚠️ Disclaimer:

This tool is for educational purposes and is not a substitute for professional clinical judgment. All treatment decisions must be made by a qualified clinician considering the individual patient’s full clinical context and local resistance data. Doses are normal-renal-function adult starting doses and must be adjusted for the individual patient.